CSHL 2021 Conference on Biology of Cancer: Microenvironment and Metastasis

CSHL 2021癌症生物学会议：微环境与转移

• 批准号: 10317580
• 负责人: DAVID J. STEWART
• 金额: $ 1.25万
• 依托单位: COLD SPRING HARBOR LABORATORY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-07-05 至 2022-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10317580
• 关键词: Archives; Area; Atmosphere; Biochemistry; Biological Models; Biophysics; Biotechnology; Cancer Biology; Cell Communication; Cells; Cellular Metabolic Process; Cellular biology; Child; Child Care; Clinic; Collaborations; Communities; Consultations; Data; Development; Diagnostic; Disease; Disease Progression; Disease Resistance; Drug Industry; Ensure; Environment; Epigenetic Process; Europe; Faculty; Fostering; Funding; Genetic; Goals; Heterogeneity; Hypoxia; Image; Immune; Immune system; Immunology; International; Investigation; Japan; Laboratories; Malignant Neoplasms; Medicine; Metabolic; Metabolism; Neighborhoods; Neoplasm Metastasis; New York; Non-Malignant; Oral; Organ; Participant; Peer Review; Physiology; Play; Postdoctoral Fellow; Process; Research; Research Institute; Research Personnel; Role; Scientist; Senior Scientist; Signal Transduction; Stromal Cells; Systems Biology; Therapeutic; Thinking; Tumor Biology; Tumor Cell Biology; Underrepresented Minority; Woman; Work; base; cancer cell; cancer initiation; cancer therapy; care systems; career; cell type; digital; drug development; exosome; graduate student; imaging modality; improved; interest; lectures; meetings; member; minority scientist; mouse model; neoplastic cell; next generation; novel therapeutic intervention; novel therapeutics; personalized cancer therapy; posters; prevent; response; role model; skills; social; success; symposium; therapy resistant; tumor; tumor heterogeneity; tumor microenvironment; tumorigenesis

Biology of Cancer: Microenvironment & Metastasis Cold Spring Harbor, New York October 12 – 16, 2021 ABSTRACT Cancer is now recognized as an abnormal organ where multiple cell types cooperate during cancer initiation and metastatic progression. Enormous progress has been made on identifying genetic, epigenetic and metabolic alterations in tumor cells and characterizing the different cell types composing a tumor, understanding the mechanisms by which these cell types interact with each other, developing ways to image the changes in a tumor and exploring therapeutic opportunities that take into account the non-malignant cells. Thus, there is an emergence of a need for an integrative approach for controlling cancer. However, most cancer meetings are organized to focus on one or two aspects of the many aspects of the biology of tumor. The proposed meeting takes an integrative approach to create a platform and bring together world leaders in different aspects of cancer biology, genetics, epigenetics, metabolism, signaling, immunology, diagnostics, and therapeutics to discuss the latest findings and promote dialogue aimed at solving the chief problems that prevent durable responses in the clinic. We believe that such an integrative approach will certainly trigger discussions and interactions that cross the disciplinary borders and find new ways to develop and deliver novel therapeutic strategies for controlling cancer. The sixth rendition of this biennial conference will draw participants from academic labs, research institutes and biotech/pharmaceutical industries, and will include leaders in the field, established investigators, junior faculty, postdoctoral fellows, graduate students and corporate scientists. To ensure the presentation of the most cutting edge results many speakers will be chosen based on the quality of abstracts submitted to the meeting coordinators and session chairs several months prior to the meeting. To maximize broad participation, efforts have been made to include outstanding women scientists and scientists from abroad as session chairs and invited speakers. Each session will be chaired by two leading scientists in the field selected by the organizers. Oral presentations will be selected from submitted abstracts by the session chairs in consultation with the organizers. Selected speakers will include graduate students, postdoctoral fellows and junior faculty aiming for maximal inclusion of young investigators. Of special importance are the two poster sessions and panel discussion. The poster session provide an opportunity for many participants to present their work in an atmosphere conducive to informal discussion and the panel discussion engages thought leaders and the participants on one highly debated topic on the role played by personalized cancer medicine in improving cancer treatment. The meeting will be of moderate size and we expect about 300 people to attend, the vast majority of whom will be presenting a poster or talk.

癌症生物学：微环境与转移 纽约州冷泉港 2021 年 10 月 12 日至 16 日 抽象的 癌症现在被认为是一种异常器官，多种细胞类型在 在识别癌症发生和转移进展方面已取得了巨大进展。 肿瘤细胞的遗传、表观遗传和代谢变化以及不同细胞的特征 构成肿瘤的类型，了解这些细胞类型相互作用的机制 相互合作，开发对肿瘤变化进行成像的方法并探索治疗方法 因此，出现了考虑非恶性细胞的机会。 需要采取综合方法来控制癌症 然而，大多数癌症会议都是如此。 组织重点关注肿瘤生物学众多方面中的一两个方面。 拟议的会议采用综合方法来创建一个平台并将世界聚集在一起 癌症生物学、遗传学、表观遗传学、新陈代谢、信号传导等不同领域的领导者 免疫学、诊断和治疗，讨论最新发现并促进对话 我们认为，旨在解决阻碍临床持久反应的主要问题。 这种综合性的方法肯定会引发跨领域的讨论和互动。 学科边界并寻找新方法来开发和提供新的治疗策略 控制癌症。 这个两年一次的会议的第六次表演将吸引来自学术实验室的参与者， 研究机构和生物技术/制药行业，并将包括该领域的领导者， 已建立的研究人员、初级教师、博士后研究员、研究生和企业 为了确保展示最前沿的成果，许多演讲者将是。 根据提交给会议协调员和会议的摘要的质量进行选择 为了最大限度地扩大广泛参与，我们在会议召开前几个月做出了努力。 邀请杰出女科学家和国外科学家担任分会主席， 每场会议将由两位由该领域选出的顶尖科学家主持。 会议组织者将从提交的摘要中选出口头报告。 与组织者协商后选定的演讲者将包括研究生， 博士后研究员和初级教师旨在最大限度地吸收年轻研究人员。 特别重要的是两次海报会议和小组讨论。 为许多参与者提供在有利的氛围中展示其作品的机会 非正式讨论和小组讨论让思想领袖和 关于个性化癌症医学在改善癌症方面所发挥的作用这一备受争议的话题 癌症治疗会议规模适中，预计约有 300 人参加。 参加，其中绝大多数人将展示海报或发表演讲。